Glofitamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and ≥2 Prior Therapies: Results From a Pivotal Phase II Expansion Study

被引：0

作者：

Dickinson, Michael ^{[1
,2
]}

Carlo-Stella, Carmelo ^{[3
,4
]}

Morschhauser, Franck ^{[5
,6
]}

Bachy, Emmanuel ^{[7
]}

Corradini, Paolo ^{[8
,9
]}

Iacoboni, Gloria ^{[10
]}

Khan, Cyrus ^{[11
]}

Wrobel, Thomasz ^{[12
]}

Offner, Fritz ^{[13
]}

Trneny, Marek ^{[14
]}

Wu, Shang-Ju ^{[15
]}

Cartron, Guillaume ^{[16
]}

Hertzberg, Mark ^{[17
,18
]}

Sureda, Anna ^{[19
]}

Perez-Callejo, David ^{[20
]}

Lundberg, Linda ^{[20
]}

Relf, James ^{[21
]}

Clark, Emma ^{[21
]}

Humphrey, Kathryn ^{[21
]}

Hutchings, Martin ^{[22
]}

机构：

[1] Royal Melbourne Hosp, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[2] Univ Melbourne, Melbourne, Vic, Australia

[3] Humanitas Univ, Milan, Italy

[4] IRCCS Humanitas Res Hosp, Milan, Italy

[5] Hop Claude Huriez, Lille, France

[6] CHU Lille, Lille, France

[7] Ctr Hosp Lyon Sud, Lyon, France

[8] Univ Milan, Milan, Italy

[9] IRCSS Ist Nazl Tumori, Fdn Ist Ricovero & Cura Carattere Sci, Milan, Italy

[10] Vall dHebron Univ Hosp, Barcelona, Spain

[11] Allegheny Hlth Network, Pittsburgh, PA USA

[12] Uniwersytet Med Wroclawiu, Wroclaw, Poland

[13] Univ Ziekenhuis Gent, Ghent, Belgium

[14] Charles Univ Hosp, Prague, Czech Republic

[15] Natl Taiwan Univ Hosp, Taipei, Taiwan

[16] CHU Montpellier, Montpellier, France

[17] Prince Wales Hosp, Sydney, NSW, Australia

[18] Univ New South Wales, Sydney, NSW, Australia

[19] Inst Catala Oncol Hosp, Barcelona, Spain

[20] F Hoffmann La Roche Ltd, Basel, Switzerland

[21] Roche Prod Ltd, Welwyn Garden City, Herts, England

[22] Rigshosp, Copenhagen, Denmark

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

ABCL; glofitamab; diffuse large B-cell lymphoma; bispecific antibody; relapsed/refractory; phase II;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ABCL-478

引用

页码：S435 / S435

页数：1

共 50 条

[41] Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma
Robertson, Michael J.
Kahl, Brad S.
Vose, Julie M.
de Vos, Sven
Laughlin, Mary
Flynn, Patrick J.
Rowland, Kendrith
Cruz, Jose C.
Goldberg, Stuart L.
Musib, Luna
Darstein, Christelle
Enas, Nathan
Kutok, Jeffery L.
Aster, Jon C.
Neuberg, Donna
Savage, Kerry J.
LaCasce, Ann
Thornton, Donald
Slapak, Christopher A.
Shipp, Margaret A.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) : 1741 - 1746
[42] Dual target dilemma: navigating epcoritamab vs. glofitamab in relapsed refractory diffuse large B-cell lymphoma
Davis, James A.
Granger, Katelynn
Sakowski, Alex
Goodwin, Sara
Herbst, Amanda
Smith, Deidra
Hendrickson, Lindsey
Nachar, Victoria R.
EXPERT REVIEW OF HEMATOLOGY, 2023, 16 (12) : 915 - 918
[43] Final results of a phase II trial of R-IDEA as salvage therapy in patients with relapsed/refractory diffuse large B-cell lymphoma
Kondo, E.
Yamamoto, K.
Masunari, T.
Takizawa, J.
Miura, K.
Masaki, Y.
Matsumura, T.
Hiramatsu, Y.
Murakam, J.
Tsujimura, H.
Tomita, N.
Maeda, Y.
Kanno, M.
ANNALS OF ONCOLOGY, 2016, 27
[44] Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO
Martin Garcia-Sancho, A.
Baile, M.
Rodriguez, G.
Dlouhy, I.
Sancho, J. M.
Jarque, I.
Gonzalez-Barca, E.
Salar, A.
Espeso, M.
Grande, C.
Bergua, J.
Montes-Moreno, S.
Redondo, A.
Enjuanes, A.
Campo, E.
Lopez-Guillermo, A.
Caballero, D.
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 203 (02) : 202 - 211
[45] Subcutaneous Epcoritamab in Relapsed or Refractory Large B-Cell Lymphoma: Pivotal Results from the Phase 2 EPCORE NHL-1 Trial
Catherine, Thieblemont
Tycel, Phillips
Herve, Ghesquieres
Cheah, Chan Y.
David, Cunningham
Do, Young R.
Tatyana, Feldman
Robin, Gasiorowski Robin
Wojciech, Jurczak
Tae, Min Kim Tae M.
Lewis, David J.
Mariolein, Van der Poe
Poon, Michelle L.
Thomas, Doerr
Nurgul, Kilavuz
Menghui, Chen
Mariana, Sacchi
Martin, Hutchings
Pieternella, Lugtenburg
Roost, Clausen Michael
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S31 - S32
[46] A Phase 3 Study of Tafasitamab Plus Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)
Larsen, Thomas S.
Manzke, Oliver
Leibovitz, Daniel
Arbushites, Michael
BLOOD, 2022, 140 : 12077 - 12078
[47] A Phase 2 Trial of AZD1152 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Collins, Graham P.
Toby, Eyre A.
Hatton, Chris S.
Radford, John
Linton, Kim M.
BLOOD, 2014, 124 (21)
[48] Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma
Kato, Koji
Makita, Shinichi
Goto, Hideki
Kanda, Junya
Fujii, Nobuharu
Shimada, Kazuyuki
Akashi, Koichi
Izutsu, Koji
Teshima, Takanori
Fukuda, Natsuko
Sumitani, Tokuhito
Sumi, Hiroyuki
Shimizu, Shinji
Kakurai, Yasuyuki
Yoshikawa, Kenji
Tobinai, Kensei
Usui, Noriko
Hatake, Kiyohiko
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (01) : 213 - 223
[49] Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma
Koji Kato
Shinichi Makita
Hideki Goto
Junya Kanda
Nobuharu Fujii
Kazuyuki Shimada
Koichi Akashi
Koji Izutsu
Takanori Teshima
Natsuko Fukuda
Tokuhito Sumitani
Hiroyuki Sumi
Shinji Shimizu
Yasuyuki Kakurai
Kenji Yoshikawa
Kensei Tobinai
Noriko Usui
Kiyohiko Hatake
International Journal of Clinical Oncology, 2022, 27 : 213 - 223
[50] Polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma
Dietliker, N.
Kiesel, H.
Mueller, R.
Mueller, A. M.
Manz, M. G.
Zenz, T.
Rosler, W.
SWISS MEDICAL WEEKLY, 2020, : 21S - 21S

← 1 2 3 4 5 →